281 related articles for article (PubMed ID: 32647070)
1. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
2. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
3. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
4. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
5. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
6. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
7. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2.
He WP; Guo YY; Yang GP; Lai HL; Sun TT; Zhang ZW; Ouyang LL; Zheng Y; Tian LM; Li XH; You ZS; Xie D; Yang GF
Int J Med Sci; 2020; 17(15):2387-2395. PubMed ID: 32922205
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
Xia Y; Ye S; Yang Y; Liu Y; Tong G
Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
[No Abstract] [Full Text] [Related]
9. Four genes relevant to pathological grade and prognosis in ovarian cancer.
Pan X; Chen Y; Gao S
Cancer Biomark; 2020; 29(2):169-178. PubMed ID: 32444534
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
12. Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer.
Zhou Q; Mei YD; Yang HJ; Tao YL
Future Oncol; 2021 May; 17(15):1889-1906. PubMed ID: 33728938
[No Abstract] [Full Text] [Related]
13. miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
Guo F; Zhang K; Li M; Cui L; Liu G; Yan Y; Tian W; Teng F; Zhang Y; Gao C; Gao J; Wang Y; Xue F
Int J Oncol; 2020 Jul; 57(1):264-276. PubMed ID: 32377701
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
15. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness.
Yin H; Wang J; Li H; Yu Y; Wang X; Lu L; Lv C; Chang B; Jin W; Guo W; Ren C; Yang G
Nat Commun; 2021 Jul; 12(1):4230. PubMed ID: 34244494
[TBL] [Abstract][Full Text] [Related]
17. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
18. Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC.
Jiang S; Zou J; Dong J; Shi H; Chen J; Li Y; Duan X; Li W
Cell Commun Signal; 2023 Jan; 21(1):9. PubMed ID: 36639771
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer.
Zhang P; Su T; Zhang S
J Immunol Res; 2021; 2021():5574176. PubMed ID: 34189143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]